Imatinib-Mesylate Induced Interstitial Pneumonitis in Two CML Patients / 결핵및호흡기질환
Tuberculosis and Respiratory Diseases
;
: 210-215, 2011.
Artigo
em Inglês
| WPRIM
| ID: wpr-182755
ABSTRACT
Imatinib mesylate, a selective inhibitor of BCR-ABL kinase activity, has demonstrated significant clinical efficacy in the treatment of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GISTs). It has become the standard of treatment for these diseases. Although the toxicity profile of imatinib is superior to that of interferon or other cytotoxic agents, some adverse events including edema, gastrointestinal toxicities and hematologic toxicities are commonly observed in the patients treated by imatinib. We present two cases of imatinib induced interstitial pneumonitis during the treatment of a chronic phase of CML.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Fosfotransferases
/
Piperazinas
/
Pirimidinas
/
Benzamidas
/
Leucemia Mielogênica Crônica BCR-ABL Positiva
/
Interferons
/
Doenças Pulmonares Intersticiais
/
Mesilatos
/
Citotoxinas
/
Tumores do Estroma Gastrointestinal
Limite:
Humanos
Idioma:
Inglês
Revista:
Tuberculosis and Respiratory Diseases
Ano de publicação:
2011
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS